Limiting the Number of Open Records in an Electronic Health Record - Reply

Jason S. Adelman; Jo R. Applebaum; William N. Southern

doi:10.1001/jama.2019.11501

Limiting the Number of Open Records in an Electronic Health Record - Reply

Jason S. Adelman, Jo R. Applebaum, William N. Southern

Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1314-1315
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	322
Issue number	13
DOIs	https://doi.org/10.1001/jama.2019.11501
State	Published - Oct 1 2019

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2019.11501

Cite this

@article{af52d9f80764477487ad9fcc08c49f43,

title = "Limiting the Number of Open Records in an Electronic Health Record - Reply",

author = "Adelman, {Jason S.} and Applebaum, {Jo R.} and Southern, {William N.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Flory reported receiving grants from the Agency for Healthcare Research and Quality, a contract from the Patient-Centered Outcomes Research Institute, and personal fees from Eli Lilly and Genentech. Dr Lipska reported receiving grants from the National Institute on Aging and Centers for Medicare & Medicaid Services and personal fees from Health Services Advisory Group. 1. Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926-1927. doi:10. 1001/jama.2019.3805 2. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):CD002967. 3. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665-2673. doi:10.2337/ dc12-0788 4. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493. doi:10. 1136/bmj.i493 5. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42 (suppl 1):S90-S102. doi:10.2337/dc19-S009 6. Aroda VR, Edelstein SL, Goldberg RB, et al; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016; 101(4):1754-1761. doi:10.1210/jc.2015-3754 Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = oct,

day = "1",

doi = "10.1001/jama.2019.11501",

language = "English (US)",

volume = "322",

pages = "1314--1315",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "13",

}

TY - JOUR

T1 - Limiting the Number of Open Records in an Electronic Health Record - Reply

AU - Adelman, Jason S.

AU - Applebaum, Jo R.

AU - Southern, William N.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Flory reported receiving grants from the Agency for Healthcare Research and Quality, a contract from the Patient-Centered Outcomes Research Institute, and personal fees from Eli Lilly and Genentech. Dr Lipska reported receiving grants from the National Institute on Aging and Centers for Medicare & Medicaid Services and personal fees from Health Services Advisory Group. 1. Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926-1927. doi:10. 1001/jama.2019.3805 2. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):CD002967. 3. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665-2673. doi:10.2337/ dc12-0788 4. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493. doi:10. 1136/bmj.i493 5. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42 (suppl 1):S90-S102. doi:10.2337/dc19-S009 6. Aroda VR, Edelstein SL, Goldberg RB, et al; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016; 101(4):1754-1761. doi:10.1210/jc.2015-3754 Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/10/1

Y1 - 2019/10/1

UR - http://www.scopus.com/inward/record.url?scp=85072759250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072759250&partnerID=8YFLogxK

U2 - 10.1001/jama.2019.11501

DO - 10.1001/jama.2019.11501

M3 - Letter

C2 - 31573633

AN - SCOPUS:85072759250

SN - 0098-7484

VL - 322

SP - 1314

EP - 1315

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 13

ER -

Limiting the Number of Open Records in an Electronic Health Record - Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this